

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
7 July 2005 (07.07.2005)

PCT

(10) International Publication Number  
**WO 2005/061486 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 401/14**,  
A61K 31/495, A61P 29/00

(21) International Application Number:  
PCT/TB2004/004187

(22) International Filing Date:  
15 December 2004 (15.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/530,763 19 December 2003 (19.12.2003) US

(71) Applicant (for all designated States except US): PHAR-  
MACIA CORPORATION [US/US]; 700 Chesterfield  
Parkway West, Chesterfield, MO 63017-1732 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SCHARTMAN,  
Richard, R. [US/US]; 5 Research Parkway, Wallingford,  
CT 06492 (US). HOFFMANN, Doug, H. [US/US]; 6854  
Pecan Avenue, Moorpark, CA 93021 (US).

(74) Agent: FULLER, Grover, F., Jr.; Pfizer Inc., P.O. Box  
1027, St. Louis, MO 63006 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: CRYSTALLINE FORM OF 2-[4-{3-(4-CHLORO-2-FLUOROPHENYL)-4-PYRIMIDIN-4-YL-1H-PYRA-  
ZOL-5-YL}PIPERIDIN-1-YL]-2-OXOETHANOL



(1)

(57) Abstract: Crystalline form of the p38 kinase inhibitor  
2-[4-{3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyra-  
zol-5-yl}piperidin-1-yl]-2-oxoethanol can be used, is provided.  
The crystalline form is a hydrated crystalline form. Also  
provided are combinations and pharmaceutical compositions  
comprising the crystalline form, process for preparing the  
crystalline form and for preparing compositions comprising the  
crystalline form, in methods for the prophylaxis and/or treatment  
of a p38 kinase-mediated condition comprising administering  
to a subject a therapeutically effective amount of the crystalline  
form of 1.